UNSPSC 51112514: Mafosfamide lysine

This classification denotes a nitrogen mustard compound with the molecular formula C9H19Cl2N2O5PS2.C6H14N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier HAC3DQ8PMS, chemically known as cis-2-((2-(bis(2-chloroethyl)amino)tetrahydro-2h-1,3,2-oxazaphosphorin-4-yl)thio)ethane sulfonate p-oxide l-lysine, but more generally known as mafosfamide lysine, which bears US NIH Compound Identifier 5362268.

European Medicines Agency schedules mafosfamide lysine or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08635MIG. Most nations, for tariff purposes, schedule mafosfamide lysine under HS 29349990. SMILES: C1CO[P@@](=O)(N[C@H]1SCCS(=O)(=O)O)N(CCCL)CCCL.C(CCN)C[C@@H](C(=O)O)N.

UNSPSC 51112514 Mafosfamide lysine is a Commodity code for a chemotherapy agent that state and local health systems, correctional facilities, and public hospitals acquire through pharmaceutical procurement channels. The code covers a single active pharmaceutical ingredient—mafosfamide lysine, a nitrogen mustard derivative used in cancer treatment protocols—that public procuring entities source through group purchasing organizations, state pharmaceutical contracts, or direct vendor relationships. State and local buyers under this code typically include department of corrections medical units, county health departments, municipal hospital systems, and state university medical centers that maintain oncology services or inpatient chemotherapy programs.

The source material provided contains no recent state and local contract opportunities tagged to UNSPSC 51112514. Without posted RFPs, RFQs, IFBs, or ITBs naming this code, geographic concentration and issuing-body prevalence cannot be determined from active solicitation data. Pharmaceutical commodities at the ingredient level often move through standing state contracts, group purchasing cooperative agreements, or blanket-order mechanisms rather than individual competitive solicitations, which may explain the absence of visible recent opportunities in public procurement channels. Firms pursuing this market should monitor state health department pharmaceutical contracts, corrections department medical supply awards, and GPO catalogs for standing vehicles under which mafosfamide lysine is listed.